- Dec 12, 2017
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
MajesTEC1 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory...
348
- Dec 10, 2017
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
IKEMA Isa-Kd Vs Kd Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In...
468
- Dec 9, 2017
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...
490
- Dec 8, 2017
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...
82
- Dec 7, 2017
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
BOSTON Study This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and...
352
- Dec 7, 2017
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple...
148